This multicenter study aims to evaluate effectiveness and safety of using the AAJT-S device as a temporary intervention for severe, atony-related PPH that is refractory to standard therapies
Age ≥18 years
Clinical diagnosis of postpartum hemorrhage (PPH) refractory to uterotonics and intrauterine balloon tamponade
Estimated blood loss greater than 1300 mL
Oral informed consent provided prior to device application
Patients with postpartum bleeding as a result of trauma, retained placenta or coagulopathy were excluded